Despite the overall low percentage of patients treated with NAT, a different rate has been observed in the various tumoral subtypes: actually, NAT was administered to 53.2% of HER2+/HR-negative patients, 27.9% of HER2+/HR+ patients, 7.1% of HER2-negative/HR-positive patients and 30.3% of triple negative breast cancer patients (Table 3). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.